Litcius/Paper detail

Single-Domain Antibody Theranostics on the Horizon

Weijun Wei, Muhsin H. Younis, Xiaoli Lan, Jianjun Liu, Weibo Cai

2022Journal of Nuclear Medicine54 citationsDOIOpen Access PDF

Abstract

Single-domain antibody (sdAb) is among the most promising vectors for developing molecular imaging tracers. Several sdAb tracers targeting human epidermal growth factor receptor 2 or programmed death ligand 1 have entered clinical practice. However, radiolabeled single-valent sdAbs generally have high kidney retention, limiting their therapeutic applications. Therefore, engineering strategies such as PEGylation or incorporation of renal cleavable linkers can be adapted to improve pharmacokinetics and reduce kidney retention. In this Focus on Molecular Imaging review, we try to summarize the latest developments in sdAb-derived agents and propose potential strategies that can be used to improve the theranostic value of radiolabeled sdAbs.

Topics & Concepts

Single-domain antibodyPEGylationLimitingNeonatal Fc receptorAntibodyComputational biologyMolecular imagingChemistryEpidermal growth factor receptorIn vivoMedicineReceptorBiologyBiochemistryImmunoglobulin GImmunologyEngineeringBiotechnologyPolyethylene glycolMechanical engineeringRadiopharmaceutical Chemistry and ApplicationsMonoclonal and Polyclonal Antibodies ResearchCAR-T cell therapy research
Single-Domain Antibody Theranostics on the Horizon | Litcius